Stapuldencel-T - Sotio

Drug Profile

Stapuldencel-T - Sotio

Alternative Names: DCVAC PCa; DCVAC/PCa; Dendritic cell vaccine/Prostate cancer - Sotio

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 06 Nov 2017 Sotio completes enrolment in the phase III VIABLE trial for Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease) in USA, United Kingdom, Czech Republic, Austria, Belarus, Denmark, France, Latvia, Lithuania, Poland, Sweden, Germany, Belgium, Serbia, Italy, the Netherlands, Hungary, Portugal, Spain, Bulgaria, Slovakia, Turkey and Croatia
  • 01 Sep 2017 Chiltern International has been acquired by Covance
  • 22 May 2017 Sotio completes a phase-II trial in Prostate cancer (Adjuvant therapy after primary radical prostatectomy, Early-stage disease) in Czech Republic (SC) (NCT02107404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top